Free Trial
→ New Rule Hits in July — The Smart Money Already Moved (From American Alternative) (Ad)
NASDAQ:SILO

Silo Pharma 3/28/2025 Earnings Report

Silo Pharma logo
$0.60 +0.01 (+1.09%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$0.60 -0.01 (-1.23%)
As of 06/23/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Silo Pharma EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Silo Pharma Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Silo Pharma Announcement Details

Quarter
Date
3/28/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Silo Pharma's next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Silo Pharma Earnings Headlines

Silo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
June 11, 2025 | finanznachrichten.de
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
June 11, 2025 | globenewswire.com
Israel-Iran WAR Could Destroy Trump's Presidency
The missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't have happened at a worse time. Trump is already dealing with Biden's $34 trillion debt bomb AND now a Middle East war. This is exactly what the "resistance" has been waiting for.
June 24, 2025 | American Alternative (Ad)
Silo Pharma, Inc. Approves $1 Million Bitcoin Purchase as Treasury Reserve Asset
June 7, 2025 | nasdaq.com
Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
June 5, 2025 | globenewswire.com
Silo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
May 23, 2025 | finanznachrichten.de
See More Silo Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma (NASDAQ:SILO) in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

View Silo Pharma Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles